Prognostic significance of telomeric repeat length alterations in pathological stage I-IIIA non-small cell lung cancer

Tomonori Hirashima; Takefumi Komiya; Takashi Nitta; Yoshiaki Takada; Masashi Kobayashi; Noriyuki Masuda; Kaoru Matui; Minoru Takada; Masanori Kikui; Tutomu Yasumitu; Atuko Ohno; Kazuhiko Nakagawa; Masahiro Fukuoka; Ichirou Kawase

Prognostic significance of telomeric repeat length alterations in pathological stage I-IIIA non-small cell lung cancer

Tomonori Hirashima, Takefumi Komiya, Takashi Nitta, Yoshiaki Takada, Masashi Kobayashi, Noriyuki Masuda, Kaoru Matui, Minoru Takada, Masanori Kikui, Tutomu Yasumitu, Atuko Ohno, Kazuhiko Nakagawa, Masahiro Fukuoka, Ichirou Kawase

Research output: Contribution to journal › Article › peer-review

36 Scopus citations

Abstract

This study was performed to evaluate the prognostic significance of alteration in telomere length in pathological stage (p-stage) I-IIIA non-small cell lung cancer (NSCLC). Paired cancer and normal lung tissues were obtained from 72 patients with histologically confirmed p-stage I-IIIA NSCLC. Terminal restriction fragment (TRF) length, which indicates telomere length, was measured by Southern blot analysis. Tumor telomerase activity was also assayed by non-radioactive PCR-ELISA in 55 patients. TRF length (mean ± SD) in normal tissue was 6.2 ± 1.1 Kb. Therefore, upper and lower limits of normal range in TRF length was set at 8.4 (mean + 2SD) Kb and 4.0 (mean - 2SD) Kb, respectively. A tumor showing TRF length over normal range was defined as positive for the alteration. In 72 patients, 25 (34.7%) with alteration in TRF length had significantly shorter survival durations than those of the others. Telomerase activity did not correlate with survival duration. In multivariate analysis, alteration in TRF length (P = 0.0033) was Second to p-stage (P = 0.0004) in importance among the various parameters.

Original language	English (US)
Pages (from-to)	2181-2187
Number of pages	7
Journal	Anticancer Research
Volume	20
Issue number	3 B
State	Published - 2000

All Science Journal Classification (ASJC) codes

Oncology
Cancer Research

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Cite this

@article{86e1e5b1eb1742b19d7f017d9c17a6ff,

title = "Prognostic significance of telomeric repeat length alterations in pathological stage I-IIIA non-small cell lung cancer",

abstract = "This study was performed to evaluate the prognostic significance of alteration in telomere length in pathological stage (p-stage) I-IIIA non-small cell lung cancer (NSCLC). Paired cancer and normal lung tissues were obtained from 72 patients with histologically confirmed p-stage I-IIIA NSCLC. Terminal restriction fragment (TRF) length, which indicates telomere length, was measured by Southern blot analysis. Tumor telomerase activity was also assayed by non-radioactive PCR-ELISA in 55 patients. TRF length (mean ± SD) in normal tissue was 6.2 ± 1.1 Kb. Therefore, upper and lower limits of normal range in TRF length was set at 8.4 (mean + 2SD) Kb and 4.0 (mean - 2SD) Kb, respectively. A tumor showing TRF length over normal range was defined as positive for the alteration. In 72 patients, 25 (34.7%) with alteration in TRF length had significantly shorter survival durations than those of the others. Telomerase activity did not correlate with survival duration. In multivariate analysis, alteration in TRF length (P = 0.0033) was Second to p-stage (P = 0.0004) in importance among the various parameters.",

author = "Tomonori Hirashima and Takefumi Komiya and Takashi Nitta and Yoshiaki Takada and Masashi Kobayashi and Noriyuki Masuda and Kaoru Matui and Minoru Takada and Masanori Kikui and Tutomu Yasumitu and Atuko Ohno and Kazuhiko Nakagawa and Masahiro Fukuoka and Ichirou Kawase",

year = "2000",

language = "English (US)",

volume = "20",

pages = "2181--2187",

journal = "Anticancer Research",

issn = "0250-7005",

publisher = "International Institute of Anticancer Research",

number = "3 B",

}

TY - JOUR

T1 - Prognostic significance of telomeric repeat length alterations in pathological stage I-IIIA non-small cell lung cancer

AU - Hirashima, Tomonori

AU - Komiya, Takefumi

AU - Nitta, Takashi

AU - Takada, Yoshiaki

AU - Kobayashi, Masashi

AU - Masuda, Noriyuki

AU - Matui, Kaoru

AU - Takada, Minoru

AU - Kikui, Masanori

AU - Yasumitu, Tutomu

AU - Ohno, Atuko

AU - Nakagawa, Kazuhiko

AU - Fukuoka, Masahiro

AU - Kawase, Ichirou

PY - 2000

Y1 - 2000

N2 - This study was performed to evaluate the prognostic significance of alteration in telomere length in pathological stage (p-stage) I-IIIA non-small cell lung cancer (NSCLC). Paired cancer and normal lung tissues were obtained from 72 patients with histologically confirmed p-stage I-IIIA NSCLC. Terminal restriction fragment (TRF) length, which indicates telomere length, was measured by Southern blot analysis. Tumor telomerase activity was also assayed by non-radioactive PCR-ELISA in 55 patients. TRF length (mean ± SD) in normal tissue was 6.2 ± 1.1 Kb. Therefore, upper and lower limits of normal range in TRF length was set at 8.4 (mean + 2SD) Kb and 4.0 (mean - 2SD) Kb, respectively. A tumor showing TRF length over normal range was defined as positive for the alteration. In 72 patients, 25 (34.7%) with alteration in TRF length had significantly shorter survival durations than those of the others. Telomerase activity did not correlate with survival duration. In multivariate analysis, alteration in TRF length (P = 0.0033) was Second to p-stage (P = 0.0004) in importance among the various parameters.

AB - This study was performed to evaluate the prognostic significance of alteration in telomere length in pathological stage (p-stage) I-IIIA non-small cell lung cancer (NSCLC). Paired cancer and normal lung tissues were obtained from 72 patients with histologically confirmed p-stage I-IIIA NSCLC. Terminal restriction fragment (TRF) length, which indicates telomere length, was measured by Southern blot analysis. Tumor telomerase activity was also assayed by non-radioactive PCR-ELISA in 55 patients. TRF length (mean ± SD) in normal tissue was 6.2 ± 1.1 Kb. Therefore, upper and lower limits of normal range in TRF length was set at 8.4 (mean + 2SD) Kb and 4.0 (mean - 2SD) Kb, respectively. A tumor showing TRF length over normal range was defined as positive for the alteration. In 72 patients, 25 (34.7%) with alteration in TRF length had significantly shorter survival durations than those of the others. Telomerase activity did not correlate with survival duration. In multivariate analysis, alteration in TRF length (P = 0.0033) was Second to p-stage (P = 0.0004) in importance among the various parameters.

UR - http://www.scopus.com/inward/record.url?scp=0033869662&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033869662&partnerID=8YFLogxK

M3 - Article

C2 - 10928174

AN - SCOPUS:0033869662

SN - 0250-7005

VL - 20

SP - 2181

EP - 2187

JO - Anticancer Research

JF - Anticancer Research

IS - 3 B

ER -

Prognostic significance of telomeric repeat length alterations in pathological stage I-IIIA non-small cell lung cancer

Abstract

All Science Journal Classification (ASJC) codes

UN SDGs

Other files and links

Fingerprint

Cite this